New Capital, Venture Capital

Busy VC 5AM eclipses $125M target for fund to inject capital into existing portfolio, meets goal for sixth biotech fund

Last October, busy VC 5AM pencilled in a $350 million target for its sixth fund. On Wednesday, it was reported that the goal was met, and the venture group’s Opportunities I fund — designed to inject more cash into its existing portfolio — had surpassed its target of $125 million, raising $147 million.

Altogether, the California-based VC — which has traditionally taken about 30 months to burn through a fund — has raised nearly $500 million for the pair of funds.

Kush Parmar

Capital raised for the Opportunities fund will be infused into 10-15 companies, 5AM said. According to a BioCentury report, $5 million – $20 million will be used in each investment.

5AM has already made one investment using Opportunities capital, managing partner Kush Parmar told Endpoints News. 5AM has a meaty portfolio of 60 biopharma companies, and the venture group has a storied history of seeding startups and taking them public.

Money from Fund VI will be used to invest in 15 companies, Parmar said. Each biopharma firm will get between $20 million and $30 million, the report added.

Andrew Schwab

5AM, run by managing partners Parmar and Andrew Schwab, previously raised $285 million for their fifth fund in the spring of 2016 and $250 million for Fund IV from 2013. Recently, 5AM led a $50 million round of funding for hearing startup Akouos.

At this point, a seventh fund is not in the offing, Parmar added.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->